**Title:** mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum

**Authors:** Valentina Di Liberto, Giuseppa Mudò, Natale Belluardo

**Affiliation:** Department of Experimental Medicine and Clinical Neuroscience, University of Palermo, Corso Tukory 129, 90134 Palermo, Italy

**Abstract:**

In the present study we aimed to verify if the enhancement of glial cell line-derived neurotrophic factor (GDNF) production in mouse striatum following treatment with LY379268 may also induce in the nigrostriatal system a time-related activation of RET receptor and its specific intracellular signaling. For this purpose, we have investigated the effects of LY379268 treatment on RET phosphorylation at the Tyr1062 and on downstream signaling Erk1/2, Akt and PLCγ1 pathway activation. The results showed that treatment with LY379268 (3 mg/kg) induces a significant increase of GDNF levels and time-related RET and Erk1/2 phosphorylation in the striatum. These increases were detected at 24 h and 48 h following LY379268 treatment. No changes were observed in the Akt and PLCγ1 phosphorylation levels. Similar results for p-Erk1/2 were observed in the substantia nigra. A complete block of LY379268 effect on striatal RET and p-Erk1/2 phosphorylation was observed in mice intrastriatal injected with anti-GDNF antibodies, suggesting a correlation between GDNF upregulation and RET activation. Overall, with present data we have shown that activation of mGluR2/3 receptors by LY379268 may be particularly promising for nigrostriatal dopaminergic system protection by enhancing striatal levels of GDNF/RET tropic system activity.

© 2011 Elsevier Ltd. All rights reserved.

---

**1. Introduction**

Gliai cell line-derived neurotrophic factor (GDNF) and its receptors constitute a physiological trophic system in the basal ganglia with critical trophic role for the maturation of dopaminergic neurons, for cell survival and fibre innervations (Li et al., 2006). Following the discovery of GDNF, several studies demonstrated that GDNF protein, infused into the nigral region, is efficacious in reducing or preventing dopaminergic toxicity in rodent models of Parkinson’s disease (Beck et al., 1995; Kearns et al., 1997; Tomac et al., 1995a; Soderstrom et al., 2006). In primate model of Parkinson’s disease, GDNF protects dopaminergic neurons in the substantia nigra, maintains dopamine levels in striatum, and improves Parkinsonian symptoms (Gash et al., 1996; Costa et al., 2001; Slevin et al., 2005). Several clinical trials using GDNF protein intrastratial infusion were also conducted in Parkinson’s disease patients (Kordower et al., 1999; Nutt et al., 2003; Gill et al., 2003; Patel et al., 2005; Slevin et al., 2005), but many of these trials reported several side effects and no improvements of disease. The delivery of GDNF to the central nervous system is challenging because GDNF is unable to cross the blood–brain barrier (Kirk et al., 2004), and several problems also come with GDNF expression induced by viral vectors, or with the use of encapsulated GDNF producing cells (Bespalov and Saarma, 2007). However, since currently GDNF raises great expectations as a potential therapeutic agent for the treatment of Parkinson’s disease and other neurodegenerative diseases, the development of drugs that administered systemically may enhance endogenous GDNF expression or activate the GDNF receptor, is an attractive idea as therapeutic option for Parkinson’s disease. In this context, recently we reported that treatment with (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), a selective mGlu2/3 receptor agonist, induces a significant enhancement of striatal GDNF and attenuates the loss of dopaminergic neurons from the substantia nigra in the MPTP mouse model (Battaglia et al., 2009).

In the adult nigrostriatal system endogenous GDNF acts as a target-derived factor for dopaminergic neurons (Tomac et al.,...
2. Material and methods

2.1. Animals

Adult male C57BL6 mice (22–24 g b.w.) from local stock have been used for the purpose of this study. The mice were kept under controlled conditions, ambient temperature 24 °C, humidity 40% and 12 h light/dark cycle with food and water ad libitum. Procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national (D.L. n. 116.G.U., suppl. 40, 18 Februrary 1992) and international laws and policies (EEC Council Directive 86/609/0j, 13L 3581, Dec. 12, 1987; NIH Guide for the Care and Use of Laboratory Animals, NIH Publication no. 80-23, 1985 and Guidelines for the Use of Animals in Biomedical Research, Thromb. Haemost. 58, 107–1084, 1987).

2.2. Treatments

Mice were treated with mGlur2/3 selective agonist LY379268 (Tocris Biosciences, Cat. N. 2453), dissolved in saline and administered systemically with a single intraperitoneal (i.p.) injection of 3 mg/kg. Control mice received the same amount of saline. Mice were sacrificed at scheduled time of 24 h, 48 h and 72 h from treatment. We also used neutralizing goat anti-GDNF antibodies (R&D Systems Cat.n. AF-212-NA) unilaterally injected into the right striatum. For striatal injection of anti-GDNF antibodies the mice, under anesthesia, were placed in a David Kopf (Tujunga, CA, USA) stereotaxic apparatus and injected using stereotaxic coordinates: A5.6, 4.6 and 3.6 mm, L1, 8 and V3 mm (Lehmann, 1974). The injection of antibodies was made in three different antero-posterior positions in order to spread the antibodies in a large area of striatum. The dose of neutralizing anti-GDNF antibodies injected in the striatum was 0.5 μg in 0.5 μl of saline and the following four groups of mice were used: group injected with saline and saline treated; group injected with saline and treated with LY379268 (3 mg/kg i.p.); group injected with neutralizing anti-GDNF antibodies (AF-212-NA, R&D Systems) and treated with LY379268; group injected with neutralizing anti-GDNF antibodies and saline; following four groups: anti-GDNF antibody in injection, all mice groups received saline or LY379268 and were sacrificed 24 h after the treatment. Mice were killed under deep anesthesia with chloral hydrate and brains were rapidly removed and striatum and substantia nigra dissected out and immediately frozen in dry ice and stored at −80 °C. For each experimental condition three independent experiments were performed and each experimental group was of at least four mice.

2.3. GDNF, p-ret, p-Erk1/2, p-akt and p-PLCγ1 analysis

Dissected tissues, striatum and substantia nigra, were homogenized at 4 °C in a buffer composed of Tris–HCl 50 mM pH 7.4, Naf 50 mM, EDTA 2 mM, protease inhibitor cocktail (P8340, Sigma–Alrich s.r.l., Milan, Italy) and phosphatase inhibitor cocktail (P5726, Sigma–Alrich s.r.l., Milan, Italy). Half of the homogenate was added with Titon X-100 1% and SDS 0.1%, left on ice for 30 min and then centrifuged at 13,000 rpm for 30 min at 4 °C. The supernatant was stored at −20 °C, aliquots were taken for protein determination by the method of Lowry et al. 1951 (LOWRY, 1951 589/0d) and 50 μg of proteins were used for GDNF, p-Erk1/2, p-PLCγ1 western blots. The remaining half of the homogenate was left on ice for 30 min and then centrifuged at 13,000 rpm for 30 min at 4 °C; the supernatant centrate was stored at −20 °C, aliquots were taken for protein determination by the method of Lowry et al. 1951 (LOWRY, 1951 589/0d) and 50 μg of proteins were used for western blotting. The samples and mol. wt. markers (16-0375, Bio-Rad Laboratories s.r.l., Segrate (MI), Italy), were run on 10% polyacrylamide gel for GDNF and p-Erk1/2, on 8% polyacrylamide gel for p-akt and on 6% polyacrylamide gel for p-PLCγ1 and p-akt at 100 V and electrophoretically transferred onto nitrocellulose membrane (Hybond-C-extra, GE Healthcare, formerly Amersham, Europe GmbH – Filiale Italiana, Milan, Italy). The membranes were incubated in 1 h in blocking buffer 1:500 (1% BSA, 0.1% Tween-20, 5% nonfat dry milk). Following three washing for 5 min. with TBS/T, the membranes were incubated with gentle shaking overnight at −4 °C with specific antibody in primary antibody dilution buffer: 1x TBS, 0.1% Tween-20, 5% BSA. The following antibodies were used: anti-GDNF antibody (AF-212-NA, R&D Systems: 1/1000) or anti-phosphorylated Erk1/2 antibody (Rabbit phospho-p44/42 MAPK, Thro2/Tyr204 antibody 1:2000; 9102 Cell Signaling), or anti-phosphorylated Akt (rabbit phospho-Akt (Ser473) antibody, 1:1000; 9271 Cell Signaling) or anti-phosphorylated PLCγ1 (rabbit phospho-PLCγ1 antibody, 1:1000; 9873 Akt antibody, 1:1000; 2821 Cell Signaling), or anti-phosphorylated RET using antibody that selectively recognizes phosphorylated RET in Tyr1062 (rabbit p-RET (Tyr1062) antibody 1:1000; sc-20252, Santa Cruz Biotechnology). Following three washing for 5 min with TBS/T, the membranes were incubated for 1 h at room temperature with anti-rabbit IgG, horseradish peroxidase-conjugated diluted 1:5000 (Sc, 2004, Santa Cruz Biotechnology) and relative bands were visualized with chemiluminescence reagent (ECL, GE Healthcare, formerly Amersham, Europe GmbH – Filiale Italiana, Milan, Italy) according to the manufacturer’s instructions. The blot is exposed to autoradiography film (Amersham Hyperfilm ECL; 28-9068-36, developed in Kodak D19 developer and fixer (Eastman-Kodak, Rochester, NY, USA), and the densitometric evaluation of bands was performed by measuring the optical density using NIH Image software. For the calculation of glutamatergic quantification of proteins, each membrane was stripped as follow: membranes were incubated at 37 °C for 30 min in buffer containing Glicina 200 mM, SDS 3 μM, 1% of Tween-20, pH 2.2. Following two washing the membranes were reprobed for detection of respective protein by using Rabbit anti-ERK1/2 antibody (9102, Cell Signaling 1:2000), or Rabbit anti-Akt antibody (9272, Cell Signaling 1:1000), or Rabbit anti-PLCγ1 antibody (2822, Cell Signaling 1:1000) or Rabbit anti-RET antibody (sc-13104, Santa Cruz Biotechnology 1:5000), Mouse anti-β-actin antibody (sc-47778, Santa Cruz Biotechnology 1:6000) was used for normalization of GDNF levels and for quantification of total proteins of RET and Erk1/2.

2.4. Statistical analysis

The bands on chemiluminescence-sensitive film (Hyperfilm ECL, GE Healthcare, formerly Amersham) from each experiment were scanned using a not self-calibrating flatbed scanner (Epson Expression 1680 Pro) at a resolution of 1200 dots per inch (dpi). The optical density was assessed using the ImageJ software (Rasband, W.S., ImageJ U.S. National Institutes of Health, Bethesda, Maryland, USA; http://rsb.info.nih.gov/ij/, 1997–2010), and the results analyzed by Prism 5 software (Graph-Pad, San Diego, CA). The data were then evaluated by one-way ANOVA with intergroup differences analysed by Fisher’s Protected Least Significan Difference LSD test, or by t-test analysis. Data, representative of three or four independent experiments with four-five mice for each experimental group, are presented as either arbitrary units, or as uncitalibrated optical density, and are expressed as mean ± SEM.
Fig. 1. Western blot analysis of GDNF and p-RET levels in the mouse striatum following LY379268 treatment (3 mg/kg). Data are representative of four independent experiments. (A–B) GDNF 24 h and 48 h, and (C–E) p-RET levels at 24 h, 48 h and 72 h from LY379268 treatment. (F) Early time-points of LY379268 treatment effect on p-RET levels. (G) RET protein levels. Histograms express the ratio of band intensity with respect to the loading control. β-actin was used for normalization of GDNF and RET proteins levels. Data are means ± SEM of optical density (OD) values obtained from films and expressed as arbitrary units. *P < 0.05, ***P < 0.001.
Fig. 2. Western blot analysis of p-Erk1/2, p-Akt and p-PLCγ1 levels in the mouse striatum and substantia nigra following LY379268 treatment (3 mg/kg). Data are representative of four independent experiments. (A–B) striatal p-Erk1/2 levels at 24 h and 48 h from LY379268 treatment; (C) p-Akt and (D) p-PLCγ1 levels in the striatum at 24 h from LY379268 treatment. (E–G) Substantia Nigra p-Erk1/2, p-Akt and p-PLCγ1 levels at 24 h from LY379268 treatment. (H) Erk1/2 protein levels. Histograms express the ratio of band intensity with respect to the loading control, β-actin was used for normalization of Erk1/2 protein levels. Data are means ± SEM of optical density (OD) values obtained from films and expressed as arbitrary units. *P < 0.05, **P < 0.01, ***P < 0.001.
3. Results

3.1. Striatal GDNF upregulation following LY379268 treatment

We first verified the striatal response of GDNF levels to LY379268 treatment using the best conditions revealed in our previous work (Battaglia et al., 2009). Specifically, mice treated with LY379268 (3 mg/kg b.w.) showed an significant increase of striatal GDNF levels both 24 h and 48 h following the treatment, as compared to saline control (Fig. 1A–B).

3.2. RET receptor activation by LY379268 was time-related to GDNF upregulation

Upon GDNF stimulation, the RET tyrosine kinase receptor is autopshorylated at a set of cytoplasmic tyrosine residues, among which Tyr1062 in the carboxyl-terminal tail has been found to be critical for GDNF signaling and for the binding of different adaptor molecules (Airaksinen and Saarma, 2002). Here we examined the effects of LY379268 treatment on activation levels of RET Tyr1062 in both substantia nigra and striatum, since RET protein has been found in the mesencephalic dopaminergic neurons and their striatal terminals (Tsuzuki et al., 1995; Glazner et al., 1998; Walker et al., 1998; Honda et al., 1999).

Concerning the striatal analysis, the results showed that treatment with LY379268 (3 mg/kg) induces a significant increase of RET phosphorylation on Tyr1062 as compared to control saline treated (Fig. 1). This increase of Tyr1062 activation was detected at 24 h and 48 h following LY379268 treatment (Fig. 1C and D) and therefore was time-related to GDNF upregulation in the striatum. The RET phosphorylation levels returned to basal condition at 72 h from LY379268 treatment (Fig. 1E). No changes were observed in the level of RET protein (Fig. 1G). The time-course of RET activation by LY379268 treatment was extended also to earlier time-points, e.g., 30 min., 1 h, and 2 h, in order to examine the potential activation of RET dependent on acute GDNF release or on its transactivation mediated by mGluR2/3 stimulation. However, the results showed no changes in the RET phosphorylation levels at any time-point examined (Fig. 1F).

The analysis of RET phosphorylation levels in the substantia nigra showed unexpectedly a very low basal RET protein level and the phosphorylated RET on Tyr1062 was undetectable in control mice and apparently not increased following LY379268 treatment (data not shown).

3.3. RET signaling pathway activation following LY379268

As above mentioned, RET receptor tyrosine kinase autophosphorylation can activate various signaling pathways including RAS/Erk1/2, PI3K/Akt, PLCγ, p38 MAPK and JNK pathways (Takahashi, 2001). Particularly, it has been demonstrated that RET phosphorylation at Tyr1062 is indispensable for the activation of the Ras/Erk or PI3K/Akt pathways (Besset et al., 2000) and is required for GDNF-mediated neuroprotection and survival of neurons (Coulpier et al., 2002). Since we found a significant increase of phosphorylated RET on Tyr1062 following LY379268 treatment, we therefore decided to examine the effects of LY379268 treatment on levels of p-Erk1/2 and p-Akt. Additionally we verified the levels of the p-PLCγ1 as Tyr1062 independent pathway, and mainly involved in neuronal differentiation.

Phosphorylation levels of p-Erk1/2, p-Akt and p-PLCγ1 were investigated both in the striatum and substantia nigra with focus on the best time-point related to upregulation of RET Tyr1062 phosphorylation. The results showed that in the striatum p-Erk1/2 was significantly increased 24 h and 48 h after LY379268 treatment (Fig. 2A and B). There was no significant change in the level of non-phosphorylated forms of ERK demonstrating that the specific activation of ERK is through post-translational modification by phosphorylation rather than regulation of protein expression. By contrast no changes were observed in the Akt (Fig. 2C) and PLCγ1 (Fig. 2D) phosphorylation levels in the striatum.

The analysis of p-Erk1/2 levels in the substantia nigra showed, like in the striatum, a significant increase at 24 h from LY379268 treatment (Fig. 2E). By contrast no changes were observed in the Akt (Fig. 2F) and PLCγ1 phosphorylation levels (Fig. 2G). The upregulation of p-Erk1/2 levels was not dependent on change in the Erk1/2 protein levels (Fig. 2H).

![Western blot analysis of p-RET and p-Erk1/2 levels in mice control or LY379268 treated and in mice preinjected in the right striatum with anti-GDNF antibodies 2 h before of LY379268 (3 mg/kg) or saline treatment. Data are representative of three independent experiments.](image-url)
3.4. Correlation between GDNF upregulation and RET activation in the striatum

To examine the causal relationship between the increase in GDNF levels and RET activation, we adopted a similar experimental approach previously developed by Battaglia et al. 2009. We used neutralizing anti-GDNF antibodies unilaterally injected into the right caudate nucleus in order to verify if block of GDNF may abrogate the RET activation and its intracellular signaling. The anti-GDNF antibodies injection was made in three different antero-posterior positions in order to spread the antibodies in a large area of striatum. The dose of neutralizing anti-GDNF antibodies was 0.5 μg/0.5 μl of saline for each injection and the following groups of mice were used: group injected with saline and saline treated; group injected with saline and treated with LY379268 (3 mg/kg i.p.); group injected with neutralizing anti-GDNF antibodies and treated with LY379268; group injected with neutralizing anti-GDNF antibodies and treated with saline. All mice 2 h after striatal injection received the saline or LY379268 treatment and were sacrificed after 24 h. The results obtained (Fig. 3A) showed a significant block of LY379268-induced RET phosphorylation in the striatum of mice treated with anti-GDNF antibodies, suggesting a correlation between GDNF upregulation by LY379268 treatment and RET activation.

In the same condition, the striatal p-Erk1/2 increase observed following LY379268 treatment was also blocked in mice injected with anti-GDNF antibodies (Fig. 3B), suggesting a functional correlation between RET activation and downstream signaling involving Erk1/2 pathway.

4. Discussion

As underlined in the introduction, this work was undertaken in order to extend our previous findings showing the ability of LY379268 to enhance the GDNF levels in the striatum and consequently to be neuroprotective in mouse model of Parkinson’s Disease (Battaglia et al., 2009). In the present study we could reveal that the enhancement of GDNF levels in mouse striatum by LY379268 treatment is followed by phosphorylation of RET receptor on Tyr1062 and that Erk1/2 is the intracellular signaling pathway linked to RET activation. In fact, the striatal p-Erk1/2 increase observed following LY379268 treatment was also blocked in mice injected with anti-GDNF antibodies (Fig. 3B), suggesting a functional correlation between RET activation and downstream signaling involving Erk1/2 pathway. Based on this upregulation of p-Erk1/2, although it needs to be further verified, we can speculate that the MAP/ERK pathway may be responsible for GDNF-mediated nigrostriatal neuroprotection observed in the MPTP mouse model of Parkinson’s disease (Battaglia et al., 2009).

In the adult striatum, endogenous GDNF expression has been detected only at very low levels and in scattered cells throughout the caudate nucleus, putamen, and internal and external segments of the globus pallidus (Battaglia et al., 2009). The diverse biological actions of GDNF are mediated through its RET receptor tyrosine kinase (Trupp et al., 1996; Yu et al., 1998; Paratcha et al., 2001) and RET protein has been found expressed in the mesencephalic dopaminergic neurons and their striatal terminals, but not in the intrastratal neurons (Trupp et al., 1997; Golden et al., 1998; Tsuchi et al., 1995; Glazner et al., 1998; Walker et al., 1998; Honda et al., 1999; He et al., 2008). However, in our hand, it was possible to detect RET protein in the striatum but not in the substantia nigra. These observations suggested that GDNF is functioning as a target-derived factor to maintain dopaminergic neuronal circuits within the basal ganglia (Barroso-Chinea et al., 2005; Tomac et al., 1995b). GDNF binding to RET receptor lead to tyrosine kinase autophosphorylation at a set of 16 cytoplasmic tyrosine residues, in the RET short and middle isoforms, and two additional tyrosines in the carboxy-terminal tail, in the RET long isoform. RET receptor tyrosine kinase autophosphorylation can activate various signaling pathways including Ras/ERK, PI3K/AKT and p38MAPK (Worby et al., 1996; Xing et al., 1998; Chiarie et al., 1998; Trupp et al., 1999; Soler et al., 1999; Hayashi et al., 2000; Takahashi, 2001; Sariola and Saarma, 2003). Particularly, it has been demonstrated that Tyr1062 is involved in the activation of Ras/Erk or PI3K/Akt pathways (Besset et al., 2000; Hayashi et al., 2000, 2001; Murakami et al., 1999a, 1999b) and is required for GDNF-mediated neurons differentiation and survival (Coulplier et al., 2002; Califano et al., 2000; De Vita et al., 2000).

In the present work, the RET phosphorylation on Tyr1062 was found linked with increased activity of Erk1/2 pathway both in the striatum and substantia nigra. By contrast, no changes were observed in the Akt and PLCγ1 phosphorylation in both brain regions.

Following neurotrophin stimulation of distal axons, multiple signaling pathways are activated locally within the axons. These include retrograde neurotrophic signaling, which plays a critical role in regulating neuronal growth, survival and differentiation of innervating neurons, and signaling molecules, such as PI3K/Akt, MAPK/Erk1/2 and Erk5 which promote local effects as axonal outgrowth and synaptic plasticity (Ginty and Segal, 2002). Increasing evidence suggest that endosomes containing neurotrophin/receptor activated complexes and other signaling proteins of the Ras/Erk1/2, p38MAPK, and PI3K/Akt pathways serve as an important source of neurotrophic retrograde signals (Wu et al., 2009; Ginty and Segal, 2002; Coulplier and Ibanez, 2004). Using an in vitro model, GDNF stimulation of distal axons resulted in activation of downstream signaling of Erk1/2 and Akt phosphorylation in the axons, and RET and Akt phosphorylation in the cell bodies, demonstrating the retrograde propagation of an intracellular GDNF-mediated signal (Coulplier and Ibanez, 2004; Tomac et al., 1995b). A retrograde propagation of GDNF signaling is also supported by data showing Erk1/2 activation in the substantia nigra following striatal GDNF injection (Salvatore et al., 2004; Lindgren et al., 2008). In the present study, following LY379268 treatment Erk1/2 signaling pathway was found significantly activated also in the substantia nigra.

Although the increased levels of phosphorylated RET were found time-related to GDNF protein upregulation, in order to verify the direct link between LY379268-induced GDNF and the RET activation we adopted the strategy based on the injection of neutralizing anti-GDNF antibodies in the striatum. The injection of anti-GDNF antibodies in the striatum was significantly able to block the effects of LY379268 on RET and Erk1/2 activation in the striatum, suggesting a GDNF-dependent RET phosphorylation following LY379268 treatment. This approach was also successful in a previous paper, where we could show that LY379268 treatment loses its neuroprotective activity after anti-GDNF antibodies implantation in the striatum (Battaglia et al., 2009). However, following LY379268 treatment we could not observe a complete block of RET phosphorylation probably because the neutralizing anti-GDNF antibodies injection in three striatal position was not enough to cover all the striatum.

The activation of mGluR2/3 have been implicated in the production of other neurotrophic factors, such as TGFβ1 in astrocytes (Bruno et al., 1998; Ciccarelli et al., 1997) and in the striatum (D’Onofrio et al., 2001), or BDNF in microglia (Matarredona et al., 2001; Venero et al., 2002), in the hippocampus (Di Liberto et al., 2010), in neuronal hippocampal cultures (Cannata et al., 2001; Wu et al., 2004; Marini et al., 1998) and in reactive astrocytes (Mudo et al., 2007; Ohishi et al., 1993, 1998). Although this proved
involvement of mGluR2/3 in neurotrophic factors regulation, the present data show that activation of mGluR2/3 receptors by LY392686 is particularly promising for the experimental treatment of Parkinson's disease, since it may protect nigrostriatal dopaminergic system by enhancing striatal levels of GDNF/RET trophic system activity.

5. Conclusions

Overall, with previous (Battaglia et al., 2009) and present data we have shown that activation of mGluR2/3 receptors by LY392686 is particularly promising for the experimental treatment of Parkinson's disease, since it may protect nigrostriatal dopaminergic system by enhancing striatal levels of GDNF/RET trophic system activity.

Acknowledgments

This work was supported by grants of MIUR (Prin 2007, 200728AAS-004); Progetti di Ateneo (Università di Palermo). DIL, supported by Ateneo di Palermo doctorate in “Scienze dell’attività motora”.

References


V. Di Liberto et al. / Neuropharmacology 61 (2011) 638–645 645
